Search research articles
Contact Us
Filters
Showing results (71-80 of 601) with videos related to
Page
of 61
Sort By:
Neurology
|
June 13, 2014
Alemtuzumab: the advantages and challenges of a novel therapy in MS
Til Menge, Olaf Stüve, Bernd C Kieseier, et al.
Neurology
|
December 25, 2003
Cyclo-oxygenases and prostaglandins in acute inflammatory demyelination of the peripheral nerve
Wei Hu, Emily Mathey, Hans-Peter Hartung, et al.
Pharmacological Research
|
September 1, 2009
The future of multiple sclerosis therapy
Bernd C Kieseier, Heinz Wiendl, Hans-Peter Hartung, et al.
Journal of the Peripheral Nervous System : JPNS
|
October 14, 2005
Tumor necrosis factor-alpha-converting enzyme is expressed in the inflamed peripheral nervous system
Martin Kurz, Heidrun Pischel, Hans-Peter Hartung, et al.
Handbook of Clinical Neurology
|
August 13, 2013
Treatment of chronic inflammatory demyelinating polyradiculoneuropathy
Helmar C Lehmann, Richard A C Hughes, Hans-Peter Hartung
Journal of the Neurological Sciences
|
June 14, 2005
Putative mechanisms of action of statins in multiple sclerosis--comparison to interferon-beta and glatiramer acetate
Oliver Neuhaus, Olaf Stüve, Juan J Archelos, et al.
Current Opinion in Neurology
|
May 6, 2025
Immunology of multiple sclerosis: an update
Patricia Kirschner, Marc Pawlitzki, Hans-Peter Hartung, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
October 27, 2012
Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod
Sebastian Jander, Bernd Turowski, Bernd C Kieseier, et al.
Current Opinion in Neurology
|
April 9, 2026
Oxidative and nitrosative damage in multiple sclerosis
Tim Prozorovski, Sven G Meuth, Hans-Peter Hartung, et al.
Journal of the Peripheral Nervous System : JPNS
|
March 13, 2016
Fampridine-PR (prolonged released 4-aminopyridine) is not effective in patients with inflammatory demyelination of the peripheral nervous system
Verena-Isabell Leussink, Mark Stettner, Clemens Warnke, et al.
Page
of 61
Search research articles
Search
Showing results (71-80 of 601) with videos related to
Sort By:
Page
of 61
Neurology
|
June 13, 2014
Alemtuzumab: the advantages and challenges of a novel therapy in MS
Til Menge, Olaf Stüve, Bernd C Kieseier, et al.
Neurology
|
December 25, 2003
Cyclo-oxygenases and prostaglandins in acute inflammatory demyelination of the peripheral nerve
Wei Hu, Emily Mathey, Hans-Peter Hartung, et al.
Pharmacological Research
|
September 1, 2009
The future of multiple sclerosis therapy
Bernd C Kieseier, Heinz Wiendl, Hans-Peter Hartung, et al.
Journal of the Peripheral Nervous System : JPNS
|
October 14, 2005
Tumor necrosis factor-alpha-converting enzyme is expressed in the inflamed peripheral nervous system
Martin Kurz, Heidrun Pischel, Hans-Peter Hartung, et al.
Handbook of Clinical Neurology
|
August 13, 2013
Treatment of chronic inflammatory demyelinating polyradiculoneuropathy
Helmar C Lehmann, Richard A C Hughes, Hans-Peter Hartung
Journal of the Neurological Sciences
|
June 14, 2005
Putative mechanisms of action of statins in multiple sclerosis--comparison to interferon-beta and glatiramer acetate
Oliver Neuhaus, Olaf Stüve, Juan J Archelos, et al.
Current Opinion in Neurology
|
May 6, 2025
Immunology of multiple sclerosis: an update
Patricia Kirschner, Marc Pawlitzki, Hans-Peter Hartung, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
October 27, 2012
Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod
Sebastian Jander, Bernd Turowski, Bernd C Kieseier, et al.
Current Opinion in Neurology
|
April 9, 2026
Oxidative and nitrosative damage in multiple sclerosis
Tim Prozorovski, Sven G Meuth, Hans-Peter Hartung, et al.
Journal of the Peripheral Nervous System : JPNS
|
March 13, 2016
Fampridine-PR (prolonged released 4-aminopyridine) is not effective in patients with inflammatory demyelination of the peripheral nervous system
Verena-Isabell Leussink, Mark Stettner, Clemens Warnke, et al.
Page
of 61